At the news
? NEUTRALIMPACT 2/10 3 filed Nov 12, 2026 at 16:03 ET
David J. Brailer filed a Form 3 initial statement of beneficial ownership upon becoming a non-executive director of Teva Pharmaceutical Industries. The filing includes a power of attorney authorizing officers to handle Section 16 reporting. No securities ownership amounts are disclosed in the filing.
- David J. Brailer appointed as non-executive director of Teva Pharmaceutical Industries Ltd.
- Form 3 filed on 2026-11-12 for period beginning 2026-11-03.
- Power of attorney executed on 2026-10-26 authorizing Dov Bergwerk, Shira Aran-Porat, and Matan Kimchi to handle Section 16 filings.
- No beneficial ownership amounts reported in the filing documents.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access